Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) released its third-quarter financial report for 2025. The company achieved total revenue of RMB 3.733 billion in the first three quarters, marking a year-on-year increase of 47.35%. Net profit attributable to shareholders reached RMB 1.616 billion, up 52.01% compared to the same period last year. Non-GAAP net profit stood at RMB 1.452 billion, reflecting a 43.62% growth. Basic earnings per share were reported at RMB 3.59.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments